| 7.29 0 (0%) | 05-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.63 | 1-year : | 8.77 |
| Resists | First : | 7.39 | Second : | 7.51 |
| Pivot price | 7.31 | |||
| Supports | First : | 7.21 | Second : | 5.99 |
| MAs | MA(5) : | 7.33  |
MA(20) : | 7.32 |
| MA(100) : | 6.71 |
MA(250) : | 5.51 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 39.4 |
D(3) : | 47.8 |
| RSI | RSI(14): 52.5 | |||
| 52-week | High : | 7.55 | Low : | 3.53 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ KZR ] has closed above bottom band by 30.4%. Bollinger Bands are 77.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 7.3 - 7.34 | 7.34 - 7.38 |
| Low: | 7.18 - 7.23 | 7.23 - 7.28 |
| Close: | 7.21 - 7.29 | 7.29 - 7.36 |
Kezar Life Sciences, Inc. is a United States-based clinical-stage biopharmaceutical company focused on identifying and advancing novel small molecule therapies. Its mission is to address significant unmet medical needs in both immune-mediated diseases and various forms of cancer. The company's most advanced experimental drug is KZR-616, a specialized immunoproteasome inhibitor. This candidate is currently undergoing Phase 2 clinical evaluation for several conditions, including lupus nephritis, dermatomyositis, and polymyositis. Concurrently, KZR-616 is also in Phase 1b clinical trials for systemic lupus erythematosus and lupus nephritis. In its preclinical pipeline, Kezar is developing KZR-261, a pioneering first-in-class protein secretion inhibitor, as well as KZR-TBD, which is being investigated for its potential in oncology and immunology. The firm was founded in 2015 and is headquartered in South San Francisco, California.
Sun, 04 Oct 2026
KZR stock exits Nasdaq after Aurinia merger closes - AD HOC NEWS
Mon, 28 Sep 2026
Kezar Life Sciences stock exits Nasdaq after merger - ad-hoc-news.de
Mon, 11 May 2026
Kezar Life Sciences Inc. (KZR) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Mon, 11 May 2026
Aurinia Pharmaceuticals completes acquisition of Kezar Life Sciences - Investing.com
Tue, 14 Apr 2026
How activist investor Kevin Tang finally landed the Bay Area company that got away from him - The Business Journals
Mon, 30 Mar 2026
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR) - Lelezard
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 15.7 (%) |
| Held by Institutions | 61.2 (%) |
| Shares Short | 152 (K) |
| Shares Short P.Month | 192 (K) |
| EPS | -6.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.56 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -29.6 % |
| Return on Equity (ttm) | -60 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -4.57 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -6.96 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -52 (M) |
| Levered Free Cash Flow | -29 (M) |
| PE Ratio | -1.19 |
| PEG Ratio | 0 |
| Price to Book value | 0.76 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|